Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Excitation Dynamics in Hetero-bichromophoric Calixarene Systems.
Tosi I, Segado Centellas M, Campioli E, Iagatti A, Lapini A, Sissa C, Baldini L, Cappelli C, Di Donato M, Sansone F, Santoro F, Terenziani F. Tosi I, et al. Chemphyschem. 2016 Jun 3;17(11):1686-706. doi: 10.1002/cphc.201501065. Epub 2016 Mar 15. Chemphyschem. 2016. PMID: 26867716
A calixarene-based fluorescent ratiometric temperature probe.
Bardi B, Tosi I, Faroldi F, Baldini L, Sansone F, Sissa C, Terenziani F. Bardi B, et al. Among authors: tosi i. Chem Commun (Camb). 2019 Jul 18;55(56):8098-8101. doi: 10.1039/c9cc04577e. Epub 2019 Jun 24. Chem Commun (Camb). 2019. PMID: 31232416
Cisplatin‑resistant germ cell tumor models: An exploration of the epithelial‑mesenchymal transition regulator SLUG.
Cardoso IIV, Rosa MN, Moreno DA, Tufi LMB, Ramos LP, Pereira LAB, Silva L, Galvão JMS, Tosi IC, Lengert AVH, Da Cruz MC, Teixeira SA, Reis RM, Lopes LF, Pinto MT. Cardoso IIV, et al. Among authors: tosi ic. Mol Med Rep. 2024 Dec;30(6):228. doi: 10.3892/mmr.2024.13352. Epub 2024 Oct 11. Mol Med Rep. 2024. PMID: 39392037 Free PMC article.
Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
Quirke-McFarlane S, Weinman J, Cook ES, Yiu ZZN, Dand N, Langan SM, Bechman K, Tsakok T, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Barbosa IA, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Galloway JB, Griffiths CEM, Barker JN, Norton S, Smith CH, Mahil SK; PsoProtect study group. Quirke-McFarlane S, et al. Br J Dermatol. 2023 Apr 20;188(5):610-617. doi: 10.1093/bjd/ljac144. Br J Dermatol. 2023. PMID: 36763806
Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial.
Fish M, Rynne J, Jennings A, Lam C, Lamikanra AA, Ratcliff J, Cellone-Trevelin S, Timms E, Jiriha J, Tosi I, Pramanik R, Simmonds P, Seth S, Williams J, Gordon AC, Knight J, Smith DJ, Whalley J, Harrison D, Rowan K, Harvala H, Klenerman P, Estcourt L, Menon DK, Roberts D, Shankar-Hari M; REMAP-CAP Immunoglobulin Domain UK Investigators. Fish M, et al. Among authors: tosi i. Intensive Care Med. 2022 Nov;48(11):1525-1538. doi: 10.1007/s00134-022-06869-w. Epub 2022 Sep 14. Intensive Care Med. 2022. PMID: 36102943 Free PMC article. Clinical Trial.
Author Correction: Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.
Andres-Ejarque R, Ale HB, Grys K, Tosi I, Solanky S, Ainali C, Catak Z, Sreeneebus H, Saklatvala J, Dand N, de Rinaldis E, Chapman A, Nestle FO, Barnes MR, Warren RB, Reynolds NJ, Griffiths CEM, Barker JN, Smith CH, Di Meglio P; PSORT Consortium. Andres-Ejarque R, et al. Among authors: tosi i. Nat Commun. 2021 Dec 16;12(1):7358. doi: 10.1038/s41467-021-27447-6. Nat Commun. 2021. PMID: 34916493 Free PMC article. No abstract available.
50 results